ALK and non-small cell lung carcinoma: This effort led to the detection of ALK fusions in 107/2009 (5.3%), ROS1 fusions in 44/2009 (2.2%), and MET ex14Δ in 31/2009 (1.5%) of NSCLC cases (Table 2).